Androgens and prevention of prostate cancer

Jamey A. Sarvis, Ian M. Thompson

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


PURPOSE OF REVIEW: This review provides a description of recent insights into the role of androgens in prostate cancer prevention. RECENT FINDINGS: Many studies have elucidated a variety of molecular mechanisms involved in the initiation and progression of prostate cancer with many directly or indirectly related to the androgen signaling pathway. Both well known and novel agents for targeting the androgen pathway are under investigation, though very few are in clinical trials. After a review of recent papers describing these mechanisms, their results and implications were summarized. SUMMARY: Finasteride remains the only agent proven to reduce the risk of prostate cancer, though there are currently two other ongoing phase III trials with vitamin E, selenium, and dutasteride. An enhanced understanding of complex interactions with the androgen pathways is leading to the exploration of additional promising approaches to mitigating the risk of prostate cancer.

Original languageEnglish (US)
Pages (from-to)271-277
Number of pages7
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number3
StatePublished - Jun 1 2008


  • Androgens
  • Chemoprevention
  • Prostate cancer
  • Prostate specific antigen

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'Androgens and prevention of prostate cancer'. Together they form a unique fingerprint.

Cite this